Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study

Evangelos Terpos, MDPhD, Efstathios Kastritis, MD, Evdoxia Hatjiharissi, MD, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD, Maria Papaioannou, MD, Argiris Symeonidis, MD PhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-140261

Published: 2020

Journal Articles

Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study

Evangelos Terpos, MDPhD, Maria Gavriatopoulou, Eirini Katodritou, MD, Evdoxia Hatjiharissi, MD, Ioanna Dialoupi, MD, Evgenia Verrou, MD, Alexandros Leonidakis, PhD, Magdalini Migkou, Sosana Delimpasi, MD, Argiris Symeonidis, MD PhD, Efstathios Kastritis, MD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140301

Published: 2020

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Association of ADAMTS13 Activity with Gender in Normal Adult Cohort

Despoina Adamidou, MD, Erasmia Rouka, Evgenia Verrou, MD, Giannis Koutsaliaris, Anna Lazaridou, MD, Despoina Kyriakou, MD, Phd

Blood (2008) 112 (11): 4554.

https://doi.org/10.1182/blood.V112.11.4554.4554

Published: 2008

Journal Articles

Differente Patterns of Telomerase Reverse Transcriptase (hTERT) mRNA Variant Expression Profiles in Patients with Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia (AML)

Evgenia Verrou, MD, Vassiliki Kaloutsi, MD, Phd, Eirini Katodritou, MD, Phd, Vasilia Garypidou, MD, Phd, Anna Nikitidou, Vassiliki Gastari, MD, Anna Lazaridou, MD, Phd, Konstantinos Zervas, MD, Phd, Vassiliki Kotoula, MD, Phd

Blood (2008) 112 (11): 4483.

https://doi.org/10.1182/blood.V112.11.4483.4483

Published: 2008

Journal Articles

Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.

Michel Delforge, MD, PhD, Eirini Katodritou, MD, PhD, Konstantinos Zervas, MD, PhD, Deniz Sargin, MD, Cyrille Hulin, MD, Mats Linderholm, MD, PhD, Evgenia Verrou, MD, Vicki Poon, MPH, Ravinder Dhawan, PhD

Blood (2007) 110 (11): 4837.

https://doi.org/10.1182/blood.V110.11.4837.4837

Published: 2007

Journal Articles

Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Dimitra Mihou, MD, Vassiliki Gastari, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD

Blood (2007) 110 (11): 2738.

https://doi.org/10.1182/blood.V110.11.2738.2738

Published: 2007

Journal Articles

The Addition of Thalidomide in Any Line of Treatment of Multiple Myeloma, Improves Overall Survival: Single Center Experience in 246 Patients.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Vassiliki Gastari, MD, Dimitra Mihou, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD

Blood (2007) 110 (11): 4813.

https://doi.org/10.1182/blood.V110.11.4813.4813

Published: 2007

Journal Articles

Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.

Blood (2007) 110 (11): 4814.

https://doi.org/10.1182/blood.V110.11.4814.4814

Published: 2007

NARROW

Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study

Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Association of ADAMTS13 Activity with Gender in Normal Adult Cohort

Differente Patterns of Telomerase Reverse Transcriptase (hTERT) mRNA Variant Expression Profiles in Patients with Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia (AML)

Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.

Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival.

The Addition of Thalidomide in Any Line of Treatment of Multiple Myeloma, Improves Overall Survival: Single Center Experience in 246 Patients.

Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only